| 7.49 0.08 (1.08%) | 10-21 11:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.97 | 1-year : | 13.17 |
| Resists | First : | 9.39 | Second : | 11.27 |
| Pivot price | 7.55  |
|||
| Supports | First : | 6.34 | Second : | 5.28 |
| MAs | MA(5) : | 7.18  |
MA(20) : | 7.98 |
| MA(100) : | 12.9 |
MA(250) : | 10.53 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 29.4 |
D(3) : | 24.1 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 17.43 | Low : | 5.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMUX ] has closed above bottom band by 44.8%. Bollinger Bands are 42.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.57 - 7.6 | 7.6 - 7.63 |
| Low: | 6.88 - 6.91 | 6.91 - 6.94 |
| Close: | 7.36 - 7.41 | 7.41 - 7.46 |
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Wed, 21 Oct 2026
Patients on an experimental multiple sclerosis drug were 2.47 times as likely to show disability improvement. - Stock Titan
Tue, 20 Oct 2026
Immunic to showcase phase 2 long-term MS disability data at MSToronto2026 - Proactive financial news
Mon, 19 Oct 2026
Immunic, Inc. (IMUX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mon, 19 Oct 2026
Immunic, Inc. (IMUX) Appoints Jaa Roberson as Chief People Officer - TradingView
Mon, 19 Oct 2026
Immunic, Inc. (IMUX) Appoints Chief People Officer - TradingView
Mon, 19 Oct 2026
Immunic Appoints Jaa Roberson as Chief People Officer - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 71.1 (%) |
| Shares Short | 2,080 (K) |
| Shares Short P.Month | 1,490 (K) |
| EPS | -3.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.9 % |
| Return on Equity (ttm) | -138.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -1.95 |
| PEG Ratio | 0 |
| Price to Book value | 0.79 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|